Miyasaki JM - Search Results

1

Miyasaki JM, Sa DS, Galvez-Jimenez N, Lang AE. Miyasaki JM, et al. Can J Neurol Sci. 2003 Mar;30 Suppl 1:S94-100. doi: 10.1017/s0317167100003292. Can J Neurol Sci. 2003. PMID: 12691482 Review.

2

Palliative care to support the needs of adults with neurological disease.

Kluger BM, Hudson P, Hanson LC, Bužgovà R, Creutzfeldt CJ, Gursahani R, Sumrall M, White C, Oliver DJ, Pantilat SZ, Miyasaki J. Kluger BM, et al. Lancet Neurol. 2023 Jul;22(7):619-631. doi: 10.1016/S1474-4422(23)00129-1. Lancet Neurol. 2023. PMID: 37353280 Review.

3

Timed up and go, cognitive, and quality-of-life correlates in Parkinson's disease.

Stegemöller EL, Nocera J, Malaty I, Shelley M, Okun MS, Hass CJ; NPF Quality Improvement Initiative Investigators. Stegemöller EL, et al. Arch Phys Med Rehabil. 2014 Apr;95(4):649-55. doi: 10.1016/j.apmr.2013.10.031. Epub 2013 Nov 27. Arch Phys Med Rehabil. 2014. PMID: 24291596

4

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Brin MF, et al. Mov Disord. 2008 Jul 30;23(10):1353-60. doi: 10.1002/mds.22157. Mov Disord. 2008. PMID: 18546321 Clinical Trial.

5

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382. JAMA Neurol. 2013. PMID: 23108692 Clinical Trial.

6

How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?

Stegemöller EL, Schmidt P, Hass C, Malaty I, Okun MS; National Parkinson Foundation Quality Improvement Initiative Investigators. Stegemöller EL, et al. Arch Phys Med Rehabil. 2015 Sep;96(9):1728-32. doi: 10.1016/j.apmr.2015.03.021. Epub 2015 Apr 14. Arch Phys Med Rehabil. 2015. PMID: 25883039

7

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. Smith KM, et al. JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472. JAMA Neurol. 2015. PMID: 25420207 Clinical Trial.

8

Effect of GPi pallidotomy on motor function in Parkinson's disease.

Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, Dostrovsky JO. Lozano AM, et al. Lancet. 1995 Nov 25;346(8987):1383-7. doi: 10.1016/s0140-6736(95)92404-3. Lancet. 1995. PMID: 7475819 Clinical Trial.

9

Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration.

Lang AE, Lozano A, Duff J, Tasker R, Miyasaki J, Galvez-Jimenez N, Hutchison W, Dostrovsky J. Lang AE, et al. Adv Neurol. 1997;74:199-211. Adv Neurol. 1997. PMID: 9348415 Review. No abstract available.

10

Acute delirium after withdrawal of amantadine in Parkinson's disease.

Miyasaki JM, Grimes D, Lang AE. Miyasaki JM, et al. Neurology. 1999 May 12;52(8):1720-1. doi: 10.1212/wnl.52.8.1717-d. Neurology. 1999. PMID: 10331717 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters